Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma

Completed · Phase 2

Conditions studied: Lymphoma

In brief

RATIONALE: Immunotoxins such as denileukin diftitox can locate cancer cells and kill them without harming normal cells. This may be an effective treatment for non-Hodgkin's lymphoma. PURPOSE: Phase II trial to study the effectiveness of denileukin diftitox in treating patients who have non-Hodgkin's lymphoma that has not responded to previous treatment.

Key facts

Study ID

NCT00003615

Run by

Eastern Cooperative Oncology Group

People needed

77

Starts

1999-05-20

Last updated by the study team

2023-06-15

Who can join

Age: 18 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Robert H. Lurie Comprehensive Cancer Center, Northwestern University — Chicago, Illinois, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• CCOP - Southern Nevada Cancer Research Foundation — Las Vegas, Nevada, United States
• Trinitas Hospital - Jersey Street Campus — Elizabeth, New Jersey, United States
• Hunterdon Regional Cancer Center — Flemington, New Jersey, United States
• Hackensack University Medical Center — Hackensack, New Jersey, United States
• Morristown Memorial Hospital — Morristown, New Jersey, United States
• Riverview Medical Center - Booker Cancer Center — Red Bank, New Jersey, United States
• Overlook Hospital — Summit, New Jersey, United States
• CCOP - Geisinger Clinic and Medical Center — Danville, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.